Table 1.

Cost-effectiveness ratios for treatment of HIV infection.

Intervention	Treatment(s)	Cost-effectiveness, US$ per QALY gained	Reference
PCP-toxoplasmosis prophylaxis	TMP-SMX	2,800	[13]
Antiretroviral therapy	AZT, 3TC, EFV	11,700	[14]
Resistance testing	…	17,900	[15]
Inpatient HIV testing	…	38,600	[16]
MAC prophylaxis	AZM	43,300	[17]
HIV testing of high-risk outpatients every 5 years	…	50,000	[18]

NOTE. AZM, azithromycin; AZT, zidovudine; EFV, efavirenz; MAC, Mycobacterium avium complex; PCP, Pneumocystis jirovecii pneumonia; QALY, quality-adjusted life-year; TMP-SMX, trimethoprim-sulfamethoxazole; 3TC, lamivudine.